| Humira (adalimumab) / AbbVie |
| Completed | 2b | 386 | US, Europe, RoW | Adalimumab, CP-690-550, CP-690,550, Placebo | Pfizer | Arthritis, Rheumatoid | 01/09 | 01/09 | | |
|
NCT01373151 / 2010-023956-99: Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate |
|
|
| Completed | 2b | 418 | Europe, Canada, Japan, US, RoW | BMS-945429 Placebo, BMS-945429, Methotrexate, Methotrexate Placebo, Adalimumab Placebo, Adalimumab | CSL Behring | Rheumatoid Arthritis | 09/12 | 06/15 | | |
|
|
| Terminated | 2b | 644 | US, Canada, Europe, RoW | Fostamatinib and placebo injections, Adalimumab and placebo of fostamatinib, Humira®, Placebo of fostamatinib, fostamatinib, and placebo injections | AstraZeneca | Rheumatoid Arthritis | 10/12 | 08/13 | | |
|
|
|
OSKIRA 4 SS, NCT02092961: Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study |
|
|
| Terminated | 2b | 198 | US, Canada, Europe, RoW | Fostamatinib, Adalimumab, Placebo of Fostamatinib, Placebo of Adalimumab | AstraZeneca | Rheumatoid Arthritis | 07/13 | 07/13 | | |
| Completed | 2b | 88 | US, Europe | New formulation adalimumab, Humira | AbbVie (prior sponsor, Abbott) | Rheumatoid Arthritis | 10/13 | 10/13 | | |
NCT00512863: A Dose-Finding Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab in Subjects With Refractory Asthma |
|
|
| Withdrawn | 2a | 272 | US | Humira (adalimumab) | Abbott | Asthma | | | | |
NCT02097264 / 2013-001492-20: A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate |
|
|
| Withdrawn | 2a | 0 | Europe | NNC0109-0012, Adalimumab, placebo | Novo Nordisk A/S | Inflammation, Rheumatoid Arthritis | 09/15 | 09/15 | | |
NCT00645814: Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis |
|
|
| Completed | 2 | 148 | US | placebo for adalimumab, placebo, adalimumab, ABT-D2E7, Humira | Abbott | Psoriasis | 09/03 | | | |
NCT00646386: Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis |
|
|
| Completed | 2 | 315 | US | adalimumab, ABT-D2E7, Humira, placebo for adalimumab, placebo | Abbott | Arthritis, Psoriatic | 04/04 | | | |
|
|
NCT00646191: Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis |
|
|
| Completed | 2 | 137 | US | adalimumab, ABT-D2E7, Humira | Abbott | Psoriasis | 06/04 | | | |
NCT00645892: Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis |
|
|
| Completed | 2 | 32 | US | adalimumab, ABT-D2E7, Humira, placebo for adalimumab, placebo | Abbott | Psoriasis | 09/04 | | | |
NCT00235833: Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis |
|
|
| Completed | 2 | 25 | Japan | adalimumab, ABT-D2E7, Humira | Abbott, Abbott Japan Co.,Ltd, Eisai Co., Ltd. | Rheumatoid Arthritis | 10/04 | | | |
NCT00645905: Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis |
|
|
| Completed | 2 | 148 | US | adalimumab, ABT-D2E7, Humira, placebo for adalimumab, placebo | Abbott | Psoriasis | 03/05 | | | |
NCT00185562: A Pilot Trial of Adalimumab for the Treatment of Osteoarthritis |
|
|
| Completed | 2 | 12 | US | Adalimumab | Stanford University | Osteoarthritis | | 01/06 | | |
NCT00055523: A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease |
|
|
| Completed | 2 | 300 | US | Adalimumab (D2E7) | Abbott | Crohn's Disease | | | | |
NCT00690846: Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum |
|
|
| Withdrawn | 2 | 0 | US | adalimumab, Humira | Wake Forest University Health Sciences | Pyoderma Gangrenosum | 07/07 | 07/07 | | |
HIDRI2007, NCT00827996: To Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa |
|
|
| Completed | 2 | 10 | US | adalimumab | Florida Academic Dermatology Centers, Abbott | Hidradenitis Suppurativa | 11/07 | 08/08 | | |
| Completed | 2 | 61 | Europe | Adalimumab, Humira, Placebos, placebo injection | University Hospital, Geneva | Sciatica | 01/08 | 06/08 | | |
| Terminated | 2 | 11 | US | Adalimumab, Humira | University of Chicago, Abbott | Sarcoidosis | 05/08 | 09/08 | | |
NCT00298272: Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis |
|
|
| Terminated | 2 | 54 | US | IDEC-C2B8 (rituximab), Rituxan, Placebo, Methotrexate, Etanercept, Enbrel, Adalimumab, Humira, Methylprednisolone, Folate | Biogen, Hoffmann-La Roche, Genentech, Inc. | Rheumatoid Arthritis | 04/09 | 07/11 | | |
2009-011763-37: THE ANTI-ANGIOGENIC EFFECTS OF ADALIMUMAB INCROHN`S DISEASE |
|
|
| Completed | 2 | 15 | Europe | Solution for injection | ISTITUTO CLINICO HUMANITAS | Crohn, s Disease | | | | |
| Completed | 2 | 311 | US, Europe | Placebo matched to atacicept, Atacicept: with loading dose, Atacicept, Adalimumab, Humira® | EMD Serono, Merck KGaA, Darmstadt, Germany | Rheumatoid Arthritis | 10/09 | 10/09 | | |
| Completed | 2 | 154 | US, Europe | adalimumab, ABT-D2E7, Humira, Placebo | Abbott | Hidradenitis Suppurativa | 03/10 | 11/10 | | |
|
NCT00525902: Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis |
|
|
| Completed | 2 | 31 | US | Adalimumab, Humira | Oregon Health and Science University, University of Illinois at Chicago, The Cleveland Clinic | Uveitis | 09/10 | 09/10 | | |
NCT01163617: The Usability and Injection Time of the Physiolis Syringe and Autoinjector in Rheumatoid Arthritis Patients |
|
|
| Completed | 2 | 85 | US | Adalimumab delivered in current syringe, ABT-D2E7, Humira, Adalimumab delivered in Physiolis syringe, Adalimumab delivered in current autoinjector, Adalimumab delivered in Physiolis autoinjector | AbbVie (prior sponsor, Abbott) | Rheumatoid Arthritis | 11/10 | 11/10 | | |
NCT00730717: Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum |
|
|
| Withdrawn | 2 | 0 | US | Humira | Wright State University, Stanford University, Wake Forest University Health Sciences | Pyoderma Gangrenosum | 12/10 | 12/10 | | |
NCT00731757: Efficacy Study of Humira in the Treatment of Cutaneous Sarcoidosis |
|
|
| Withdrawn | 2 | 0 | US | Humira | Wright State University, Stanford University | Sarcoidosis, Cutaneous Sarcoidosis | 12/10 | 12/10 | | |
NCT00514982: Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome |
|
|
| Withdrawn | 2 | 0 | US | Mesalamine, Infliximab, Corticosteroids, 6-Mercaptopurine, Tacrolimus, Adalimumab | National Institute of Allergy and Infectious Diseases (NIAID) | Hermanski-Pudlak Syndrome, Colitis, Cytokines, Lymphocytes, Drug Evaluation | 03/11 | 03/11 | | |
NCT01136252 / 2009-017429-21: Intravitreal Adalimumab in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration |
|
|
| Completed | 2 | 5 | Europe | Adalimumab, Humira® | Hospital Universitari Vall d'Hebron Research Institute | Age-Related Macular Degeneration, Choroidal Neovascularization | 09/11 | 10/11 | | |
NCT00274352: A Study of Adalimumab to Treat Sarcoidosis of the Skin |
|
|
| Completed | 2 | 16 | US | adalimumab | Pariser, Robert J., M.D., Abbott, Virginia Clinical Research, Inc. | Sarcoidosis | 02/12 | 02/12 | | |
2008-006885-27: EFFICACY AND SAFETY OF ADALIMUMAB (HUMIRA®) IN PATIENTS WITH PERIPHERAL SPONDYLOARTHRITIS WITHOUT ANKYLOSING SPONDYLITIS OR PSORIATIC ARTHRITIS |
|
|
| Completed | 2 | 40 | Europe | adalimumab, Solution for injection, Humira | Clinical Immunology and Rheumatology | PERIPHERAL SPONDYLOARTHRITIS WITHOUT ANKYLOSING SPONDYLITIS OR PSORIATIC ARTHRITIS | | | | |
NCT01225393 / 2010-021577-37: A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis |
|
|
| Completed | 2 | 211 | US, Europe, RoW | MLTA3698A, adalimumab, leflunomide, methotrexate, placebo | Genentech, Inc. | Rheumatoid Arthritis | 07/12 | | | |
|
| Completed | 2 | 61 | Canada, Europe, RoW | Adalimumab, Humira, ABT-D2E7 | AbbVie (prior sponsor, Abbott) | Rheumatoid Arthritis | 11/12 | 11/12 | | |
| Completed | 2 | 64 | Europe | Adalimumab, Humira, ABT-D2E7 | AbbVie (prior sponsor, Abbott) | Rheumatoid Arthritis | 11/12 | 11/12 | | |
| Completed | 2 | 293 | US, Canada, Europe | CNTO 1959 (5 mg), CNTO 1959 (15 mg), CNTO 1959 (50 mg), CNTO 1959 (100 mg), CNTO 1959 (200 mg), Adalimumab, Placebo | Janssen Inc. | Psoriasis | 11/12 | 08/13 | | |
|
|
|
|
|
|
2009-015749-22: A prospective, monocentric clinical trial with adalimumab for topical treatment of chronic wounds Eine prospektive, monozentrische klinische Prüfung von Adalimumab zur topischen Behandlung von chronischen Wunden |
|
|
| Completed | 2 | 18 | Europe | Humira, Solution for injection, Humira | University of Leipzig, Abott Germany | Chronic stasis ulcer, Chronic wound chronische Wunde, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
NCT01712178 / 2012-000535-36: A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety |
|
|
| Completed | 2 | 100 | US, Europe | Adalimumab, current formulation, Humira, Adalimumab, new formulation | AbbVie (prior sponsor, Abbott) | Rheumatoid Arthritis | 05/13 | 05/13 | | |
| Completed | 2 | 32 | US, Canada | Adalimumab, Lisinopril, losartan, and atorvastatin, galactose | NYU Langone Health, University of Michigan, The Cleveland Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Focal Segmental Glomerulosclerosis | 06/13 | 02/14 | | |
NCT01872546: Skin Transcriptional Profiles In Psoriatic Patients Under Adalimumab Biotherapy |
|
|
| Completed | 2 | 15 | Europe | HUMIRA 40mg | Poitiers University Hospital | Chronic Plaque Psoriasis | 09/13 | | | |
NCT02015793: Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease |
|
|
| Completed | 2 | 30 | NA | Adalimumab, Placebo for adalimumab | AbbVie | Crohn's Disease | 02/15 | 02/15 | | |
|
| Completed | 2 | 60 | | | A/Prof Stephen Oakley, Abbott Pharmaceuticals | Rheumatoid Arthritis, Cardiovascular Disease | | | | |
NCT02141997 / 2013-004019-37: A Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate |
|
|
| Completed | 2 | 222 | US, Europe, RoW | adalimumab, Humira, ABT-122 | AbbVie | Rheumatoid Arthritis | 09/15 | 11/15 | | |
|
2005-005544-79: Adalimumab (Humira) as add-on therapy in the treatment of patients with severe persistent therapy resistant asthma |
|
|
| Terminated | 2 | 30 | Europe | Humira, Not Available, Solution for injection, Humira | The Clinical Research Centre, RCSI Education and Research Centre | Severe Asthma | | | | |
2006-003564-57: Adalimumab (anti TNF alfa) in the management of acute lumbar disc prolapses -a one year, randomized, placebo controlled, double blind, single center trial |
|
|
| Ongoing | 2 | 99 | Europe | Humira 40 mg injektioneste, liuos esitäytetyssä kertakäyttöruiskussa, Humira 40 mg injektioneste, liuos esitäytetyssä kertakäyttöruiskussa | Kuopio University Hospital | Patients with acute or subacute (no more than 2 months) clinical sciatica caused by herniated disc prolapse | | | | |
2006-005426-23: Evaluation of the efficacy and safety of adalimumab (Humira) s.c. injections eow. in patients with adhesive capsulitis (frozen shoulder). |
|
|
| Terminated | 2 | 30 | Europe | Solution for injection, Humira, Diprospan Xylocain 1 % | Pierre Schydlowsky | Frozen shoulder, e.g. adhesive capsulitis | | | | |
2006-003146-41: A CONTROLLED RANDOMIZED DOUBLE-BLIND MULTICENTER STUDY COMPARING TWO THERAPY STRATEGIES IN DMARD-NAIVE EARLY RHEUMATOID ARTHRITIS PATIENTS OVER 48 WEEKS: INDUCTION THERAPY WITH ADALIMUMAB AND METHOTREXATE OVER 24 WEEKS FOLLOWED BY METHOTREXATE MONOTHERAPY UP TO WEEK 48 VS. METHOTREXATE MONOTHERAPY |
|
|
| Completed | 2 | 250 | Europe | HUMIRA, Metex, Humira, Metex, Humira, Metex | Charité-Universitätsmedizin Berlin; Department of Rheumatology and Clinical Immunology | Musculoskeletal disorders | | 04/11 | | |
2010-021141-41: Randomised Control Trial of the Clinical Effectiveness, Safety and Cost Effectiveness of Adalimumab in Combination with Methotrexate for the Treatment of Juvenile Idiopathic Arthritis Associated Uveitis. |
|
|
| Ongoing | 2 | 154 | Europe | Adalimumab (40mg), Adalimumab (20mg), | University Hospitals Bristol NHS Foundation Trust | Juvenile Idiopathic Arthritis Associated Uveitis | | | | |
NCT02349451 / 2014-003558-15: A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX) |
|
|
| Completed | 2 | 240 | NA | adalimumab, Humira, ABT-D2E7, ABT-122, remtolumab | AbbVie | Psoriatic Arthritis | 07/16 | 07/16 | | |
NCT01716039: Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC) |
|
|
| Terminated | 2 | 22 | NA | MTX 12.5, MTX, MTX 25, Adalimumab, Humira | Alimentiv Inc., Abbott | Ulcerative Colitis | 07/16 | 07/16 | | |
| Completed | 2 | 11 | Europe | Adalimumab, Humira | Assistance Publique - Hôpitaux de Paris | Netherton Syndrome | 12/16 | 09/17 | | |
| Completed | 2 | 22 | Europe | Adalimumab, Methotrexate, Placebo, Folic Acid | University of Leeds, Abbott | Oligoarthritis | 01/17 | 01/17 | | |
NCT00690911: Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis |
|
|
| Withdrawn | 2 | 0 | US | adalimumab, Humira | Wake Forest University | Sarcoidosis | | | | |
HHRA-2, ACTRN12615000557538: HUNTER HEART-RA-2 () STUDY
A Randomised Controlled Trial Evaluating the Effects of Humira Upon Cardiovascular Risk as Measured by Endothelial Function in patients with Rheumatoid Arthritis who Test Positive for Anti-CCP Antibodies as well as those who Test Negative for Anti-CCP Antibodies. |
|
|
| Terminated | 2 | 70 | | | A/Prof Stephen Oakley, Abbvie Inc | Rheumatoid Arthritis, Cardiovascular Disease | | | | |
NCT02833350 / 2016-000335-40: Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) |
|
|
| Completed | 2 | 578 | Europe, US, RoW | GDC-0853, RO7010939, Adalimumab, Folic Acid, MTX, Placebo | Genentech, Inc. | Rheumatoid Arthritis | 07/18 | 07/18 | | |
NCT03248531 / 2017-000892-10: A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa. |
|
|
| Completed | 2 | 90 | Europe, US, RoW | Bimekizumab, UCB4940, Adalimumab, Humira®, Placebo | UCB Biopharma SRL | Hidradenitis Suppurativa | 11/18 | 02/19 | | |
2017-000519-18: PIMOC : Personalized targeted therapies in inflammatory complex multi organ disease Personnalisation des traitements de Pathologies Inflammatoires Multi Organes Complexes : PIMOC |
|
|
| Not yet recruiting | 2 | 32 | Europe | SECUKINUMAB, ADALIMUMAB, ANAKINRA, RITUXIMAB, TOCILIZUMAB, USTEKINUMAB, Solution for injection, Solution for infusion | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), DGOS | Patients presenting inflammatory non classified disease targeting at least 2 organs involvement: skin, lymph nodes, hemopoietic system, joints, digestive tract. The disease has been resistant to at least two prior lines of treatment. Patient(e) présentant une maladie inflammatoire mal classée, impliquant au moins deux organes dont au moins la peau, et un des suivants : ganglions lymphatiques, système hématopoïétique, articulations, appareil digestif. La maladie a été résistante à au moins deux lignes de traitement., Patients presenting inflammatory non classified disease, resistant to prior treatment patients présentant une maladie inflammatoire non classée, sévère et résistante, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT02929251: Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory Uveitis |
|
|
| Completed | 2 | 112 | Europe | Anakinra, Tocilizumab, Adalimumab | Assistance Publique - Hôpitaux de Paris | Uveitis, Biotherapy | 10/21 | 01/22 | | |
NCT02983227 / 2016-000498-19: A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350 |
|
|
| Completed | 2 | 496 | Europe, US, RoW | GDC-0853, RO7010939 | Genentech, Inc. | Rheumatoid Arthritis | 07/19 | 07/19 | | |
|
NCT02456363: Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis |
|
|
| Unknown status | 2 | 300 | RoW | TNF alpha, Drug: Adalimumab (Humira), Drug: Etanercept (Enbrel), Drug: Golimumab (Simponi), NSAIDs and sulfasalazine, Drug: Arcoxia, Drug: Celebrex, Drug: Tonec, Drug: Mobic, Drug: sulfasalazine | Chung Shan Medical University | Ankylosing Spondylitis | 10/19 | 12/19 | | |
2017-003249-18: TIGERS study proposes to take mini fragments of synovial tissue to study the molecular patterns present in psoriatic arthritis, in order to to identify markers of disease progression and response to treatment with Ustekinumab, Guselkumab or Adalimumab to analyze and compare different expression patterns within synovial and cutaneous tissue , and to investigate whether molecular diagnosis allows to predict the evolution of the disease in the long term, as well as the therapeutic response. |
|
|
| Completed | 2 | 36 | Europe | Ustekinumab, adalimumab, L04AC05, Powder and solvent for solution for injection, Solution for infusion, Solution for injection in pre-filled syringe, Tremfya 100 mg solution for injection in pre-filled syringe., STELARA® 45 mg/0.5 mL or 90 mg/mL solution in a single-dose prefilled syringe, Humira 40 mg solution for injection in pre-filled syringe | Cliniques Universitaires Saint-Luc, Janssen Pharmaceutica | Psoriatic arthritis (PsA), Psoriatic arthritis (PsA) is a type of chronic inflammatory arthritis, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT03823391 / 2018-003053-21: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA) |
|
|
| Completed | 2 | 48 | Europe, US, RoW | ABBV-3373, Placebo for ABBV-3373, Adalimumab, Humira, Placebo for adalimumab | AbbVie, Abbvie Inc. | Rheumatoid Arthritis (RA) | 04/20 | 08/20 | | |
2018-003053-21: A Clinical Study Testing the Safety, Properties, and Treatment Effects of an Antibody Drug Conjugate ABBV-3373 in Comparison with the Antibody Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis |
|
|
| Not yet recruiting | 2 | 45 | Europe | Adalimumab, ABBV-3373, Powder for solution for injection, Solution for injection in pre-filled syringe, Humira (adalimumab) | AbbVie Deutschland GmbH & Co. KG, Abbvie Inc. | Moderate to Severe Rheumatoid Arthritis, The body's immune system attacks the joints, creating inflammation that cause the synovium to thicken. Resulting in swelling and pain in and around the joints. This can cause permanent joint damage., Diseases [C] - Immune System Diseases [C20] | | | | |
| Completed | 2 | 140 | Europe | Adalimumab, Humira, Saline | University of Oxford, Department of Health, United Kingdom, Wellcome Trust, 180 Therapeutics LP | Dupuytren's Disease | 11/20 | 12/20 | | |
| Completed | 2 | 62 | Canada | Adalimumab 40 mg, Humira, Placebo | Canadian Research & Education in Arthritis, AbbVie | Osteoarthritis, Knee | 03/21 | 03/21 | | |
| Withdrawn | 2 | 0 | NA | BT-11, Active comparator | NImmune Biopharma | Crohn's Disease | 02/22 | 02/22 | | |
| Completed | 2 | 51 | Europe, RoW | AMT-101 (oral), Placebo (oral), Humira (adalimumab) | Applied Molecular Transport, Applied Molecular Transport Inc. | Ulcerative Colitis | 06/22 | 07/22 | | |
2020-002833-13: A study of AMT-101 in combination with Adalimumab in patients with Ulcerative Colitis. |
|
|
| Not yet recruiting | 2 | 50 | Europe | AMT-101, Gastro-resistant tablet, Solution for injection in pre-filled pen, Humira | Applied Molecular Transport Inc., Applied Molecular Transport Inc. | Ulcerative Colitis, Ulcerative colitis is a form of inflammatory bowel disease (IBD) that causes inflammation and ulcers in the colon resulting in abdominal pain and bloody diarrhea, Diseases [C] - Digestive System Diseases [C06] | | | | |
2022-001316-26: UVB: treatment of UVeitis in Behçet’s diseases with biologics |
|
|
| Not yet recruiting | 2 | 60 | Europe | Solution for injection in pre-filled pen, Solution for injection in pre-filled syringe, Humira 40mg, solution injectable en stylo prérempli, RoActemra 162 mg solution injectable en seringue préremplie | Assistance Publique Hôpitaux de Paris / DRCI, French Ministry of health | severe uveitis of Behçet’s disease, severe uveitis of Behçet’s disease, Diseases [C] - Immune System Diseases [C20] | | | | |
LYRA, NCT04988308: A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa |
|
|
| Terminated | 2 | 151 | Europe, Canada, Japan, US, RoW | Bermekimab, JNJ-77474462, Adalimumab, Placebo | Janssen Research & Development, LLC | Hidradenitis Suppurativa | 10/22 | 11/22 | | |
2020-002607-19: A Dose-ranging Study of Bermekimab (JNJ-77474462) in the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa |
|
|
| Completed | 2 | 300 | Europe | bermekimab, HUMIRA®, JNJ-77474462, Solution for injection in pre-filled syringe, HUMIRA® | Janssen-Cilag International NV, Janssen Research & Development, LLC | Moderate to Severe Hidradenitis Suppurativa, Acne inversa, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
NCT05155592: Reduction or Discontinuation of TNF-α Inhibitor in Non-infectious Uveitis Patients |
|
|
| Recruiting | 2 | 28 | RoW | reduction or discontinuation of Adalimumab | Dan Liang | Uveitis, Adalimumab | 01/23 | 04/23 | | |
2021-005947-58: Evaluation of Sonelokimab in Patients with Active Psoriatic Arthritis Zhodnocení přípravku sonelokimab u pacientů s aktivní psoriatickou artritidou |
|
|
| Not yet recruiting | 2 | 200 | RoW, Europe | Sonelokimab, adalimumab, Solution for injection in pre-filled syringe, Humira® | MoonLake Immunotherapeutics AG, MoonLake Immunotherapeutics AG | Active Psoriatic Arthritis, Chronic, inflammatory disease of the joints and the places where tendons and ligaments connect to bone., Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
| Completed | 2 | 234 | Europe, Canada, US | Sonelokimab (M1095), Adalimumab, Placebo | MoonLake Immunotherapeutics AG, MoonLake Immunotherapeutics AG | Hidradenitis Suppurativa | 05/23 | 08/23 | | |
| Withdrawn | 2 | 0 | US | JNJ-64304500, Placebo, Adalimumab, Ustekinumab | Janssen Research & Development, LLC | Crohn Disease | 05/23 | 09/23 | | |
2021-005928-38: Evaluation of Sonelokimab for the treatment of patients with active moderate to severe HS |
|
|
| Not yet recruiting | 2 | 210 | Europe, RoW | Sonelokimab, adalimumab, Solution for injection in pre-filled syringe, Humira® | MoonLake Immunotherapeutics AG, MoonLake Immunotherapeutics AG | Active moderate to severe hidradenitis suppurativa, Pain due to a skin condition that causes small, painful lumps to form under the skin and scarring on the skin., Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
NCT04009668: Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease |
|
|
| Completed | 2 | 7 | US | adalimumab, Humira | University of Michigan | FSGS, MCD, Focal Segmental Glomerulosclerosis, Minimal Change Disease | 09/23 | 10/23 | | |
| Completed | 2 | 207 | Europe, US, RoW | Sonelokimab, M1095, Placebo, Adalimumab | MoonLake Immunotherapeutics AG, MoonLake Immunotherapeutics AG | Arthritis, Psoriatic | 09/23 | 01/24 | | |
NCT04588818: Adalimumab Plus Methotrexate for the Treatment of Pediatric Uveitis |
|
|
| Recruiting | 2 | 30 | RoW | Adalimumab plus Methotrexate | Sun Yat-sen University | Uveitis | 12/23 | 12/23 | | |
NCT06242652: A Study to Evaluate 608 in Patients with Ankylosing Spondylitis (AS) |
|
|
| Active, not recruiting | 2 | 250 | RoW | 608 Dose A, SSGJ-608 Dose A, 608 Dose B, SSGJ-608 Dose B, 608 Dose C, SSGJ-608 Dose C, Adalimumab, Humira, Placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Ankylosing Spondylitis | 02/25 | 06/25 | | |
NCT06257875: A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis |
|
|
| Active, not recruiting | 2 | 156 | Europe, Canada, Japan, US, RoW | Lutikizumab, ABT-981, Adalimumab, Humira | AbbVie | Ulcerative Colitis | 09/27 | 09/27 | | |
| Recruiting | 2 | 36 | Europe | Adalimumab-800CW, Humira, Fluorescence Imaging, Quantified fluorescence molecular endoscopy | University Medical Center Groningen, AbbVie | IBD, Rheumatoid Arthritis | 03/26 | 08/26 | | |
| Recruiting | 2 | 32 | Europe | Kineret, Humira, Stelara, Cosentyx, Roactemra, Rituximab | Assistance Publique - Hôpitaux de Paris, URC-CIC Paris Descartes Necker Cochin | Inflammatory Disease, Autoimmune Diseases | 11/25 | 11/25 | | |
NCT06849908: Baricitinib in the Treatment of Intestinal Behçet's Syndrome |
|
|
| Recruiting | 2 | 56 | RoW | Baricitinib, Olumiant®, Adalimumab, Humira® | Peking Union Medical College Hospital | Behcet Syndrome, Intestinal Type | 06/27 | 06/28 | | |
2006-001816-56: Can PET scan be used to assess disease activity in patients with sarcoidosis during treatment with adalimumab (Humira)? |
|
|
| Completed | 2 | 10 | Europe | Humira, Injection*, Humira | Rigshospitalet | sarcoidosis | | | | |
2006-001684-34: Adalimumab clinical trial in plaque psoriasis – effect on expression of TNF-a and MAP-kinases in psoriatic skin – ACTION An open-label trial investigating adalimumab (HUMIRA) 80 mg s.c. at week 0 followed by 40 mg s.c. every other week for 12 weeks in patients with plaque psoriasis eligible for biological therapy |
|
|
| Completed | 2 | 8 | Europe | adalimumab/HUMIRA, Solution for injection | Knud Kragballe, Dermatological Department, Århus Sygehus (Hospital) | Patients with psoriasis vulgaris (plaque psoriasis) | | | | |
2005-004301-28: Treatment of painful knee osteoarthrosis with adalimumab (Humira (R)): Open-label study to evaluate safety and efficacy |
|
|
| Completed | 2 | 20 | Europe | Humira, Injection*, Humira | KAS Glostrup | Osteoarthrosis | | | | |
2006-005297-48: Adalimumab s.c. for the treatment of patients with hidradenitis suppurativa – clinical efficacy, safety and tolerability - SOPHISTICATE |
|
|
| Completed | 2 | 30 | Europe | Solution for injection, HUMIRA | University of Copenhagen, Roskilde, Department of Dermatology | Patients with hidradenitis suppurativa | | | | |
TIMPANI, NCT05590455: Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis |
|
|
| Recruiting | 2 | 130 | RoW | Adalimumab Injection | ANRS, Emerging Infectious Diseases | Tuberculous Meningitis, HIV I Infection | 06/27 | 12/27 | | |
NCT06037811: Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis |
|
|
| Recruiting | 2 | 30 | Canada | Adalimumab, Prednisone | Tom Appleton, Canadian Research Group in Immuno-Oncology, Western University | Inflammatory Arthritis, Immune-related Adverse Event | 11/25 | 11/25 | | |
PROSECT RP, NCT06941376: An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis |
|
|
| Recruiting | 2 | 20 | US | Methotrexate (MTX), Azathioprine (AZA), Adalimumab, Infliximab, Tocilizumab | University of Pennsylvania | Relapsing Polychondritis | 07/27 | 12/27 | | |
NCT07138898: Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty |
|
|
| Not yet recruiting | 2 | 80 | US | Methotrexate, Sulfasalazine, Hydroxychloroquine, Plaquenil, Leflunomide, Arava, Azathioprine, Imuran, Mycophenolate, Cellcept, Cyclosporine, Tacrolimus, Etanercept, Enbrel, Adalimumab, Humira, Golimumab, Simponi, Certolizumab, Cimzia, Infliximab, Remicaide, Rituximab, Rituxan, Belimumab, Benlysta, Tocilizumab, Actemra, Anakinra, Kineret, Canakinumab, Ilaris, Abatacept, Orencia, Secukinumab, Cosentyx, Ixekizumab, Taltz, Bimekizumab, Bimzelx, Ustekinumab, Stelara, Guselkumab, Tremfya, Risankizumab, Skyrizi, Tofacitinib, Xeljanz, Upadacitinib, Rinvoq | NYU Langone Health | Rheumatic Disease | 09/27 | 09/27 | | |
PRISMS, NCT06996652: An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD) |
|
|
| Not yet recruiting | 2 | 108 | US | Adalimumab, Placebo | Yale University, The Marcus Foundation | REM Sleep Behavior Disorder | 04/28 | 04/28 | | |
NCT07151937: A Study of LAD191 in Adults With Hidradenitis Suppurativa |
|
|
| Not yet recruiting | 2 | 200 | NA | LAD191, Placebo, Adalimumab | Almirall, S.A. | Hidradenitis Suppurativa | 05/27 | 11/27 | | |
| Not yet recruiting | 2 | 120 | NA | Adalimumab, Ustekinumab, Baricitinib | Assistance Publique - Hôpitaux de Paris | Folliculitis Decalvans (FD) | 11/29 | 04/30 | | |
ChiCTR2400087021: An open, single-arm study of high-intensity focused ultrasound (HIFU) combined with Adebrelimab and XELIRI for the second-line treatment of locally advanced or metastatic pancreatic cancer |
|
|
| Not yet recruiting | 2 | 20 | | High-intensity focused ultrasound therapy (HIFU) combined with adalimumab and XELIRI | The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital); The First Affiliated Hospital of Nanjing Medical University, Self recruitment | pancreatic cancer | | | | |
| Not yet recruiting | 2 | 60 | NA | Adalimumab, Tocilizumab | Assistance Publique - Hôpitaux de Paris, French Ministry of health | Behcet's Uveitis | 11/26 | 07/27 | | |
ChiCTR2500109171: A single-arm, prospective, single-center clinical study of adbelebiantumab combined with TP chemotherapy regimen for neoadjuvant treatment of locally advanced hypopharyngeal cancer (XMHNC-001) |
|
|
| Not yet recruiting | 2 | 34 | | Two cycles of neoadjuvant therapy: Adalimumab 1200mg, intravenous infusion, Day 1, every 3 weeks; Albumin-based paclitaxel 260mg/m2, intravenous infus | The First Affiliated Hospital of Xiamen University; The First Affiliated Hospital of Xiamen University, A single-arm, prospective, single-center clinical study of adbelebiantumab combined with TP chemothe | Patients with locally advanced hypopharyngeal cancer | | | | |
| Recruiting | 2 | 70 | US | Adalimumab, Placebo will be administered subcutaneously every 2 weeks, for a total of 6 injections. | NorthShore University HealthSystem, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Benign Prostatic Hyperplasia (BPH) | 04/28 | 06/28 | | |
ChiCTR2500108269: Phase II Clinical Study of the Combination of Irinotecan Liposome II, Gemcitabine, Albumin-Bound Paclitaxel, and Adalimumab for the Conversion Therapy of Locally Advanced Pancreatic Cancer. |
|
|
| Not yet recruiting | 2 | 45 | | Combination of Irinotecan Liposome II, Gemcitabine, Albumin-Bound Paclitaxel, and Adalimumab | Chinese PLA General Hospital & Medical School; Chinese PLA General Hospital & Medical School, Jiangsu Hengrui Pharmaceutical Co., Ltd | pancreatic cancer | | | | |
| Completed | 1/2 | 20 | Canada | adalimumab, Humira | University of Alberta | Osteoarthritis | 11/10 | 11/10 | | |
